Quantcast

Latest Kinex Pharmaceuticals Stories

2014-07-01 08:30:48

BUFFALO, N.Y., July 1, 2014 /PRNewswire/ -- Kinex Pharmaceuticals announced today that Dr. Jean-Pierre Sommadossi has elected to step down from the Board of Directors of Kinex but will continue to support the company as a Senior Advisor to the CEO. After an extensive search, the Board has appointed Michael P. Murphy to the Board of Directors to fill the Board seat vacated by Dr. Sommadossi. Mr. Murphy is a Senior Partner in DLA Piper (one of the world's preeminent law firms and the...

2014-06-30 12:31:55

BUFFALO, N.Y. and SEOUL, South Korea, June 30, 2014 /PRNewswire/ -- Hanmi Pharmaceuticals announces a positive study on Oraxol® use in a Phase I/II clinical proof-of-concept study (Study HM-OXL-201) of Oraxol - an oral form of the approved drug paclitaxel, with HM30181, a highly potent and selective, P-glycoprotein inhibitor of the gastro-intestinal tract. The study, entitled "A phase I-II clinical trial to determine the recommended dose and to assess the efficacy, safety and...

2014-05-13 08:33:45

BUFFALO, N.Y., May 13, 2014 /PRNewswire/ -- Kinex Pharmaceuticals announces the addition of two key executives to its clinical leadership team reporting to Chief Medical Officer, Dr. Rudolf Kwan. Douglas Kramer MD joins Kinex as Vice President of Clinical and Regulatory Affairs and Jane Devane has joined Kinex as Director of Clinical Operations. Dr. Kramer adds significant regulatory and clinical risk management experience and was previously a Medical Officer for the United...

2014-03-19 16:23:55

BUFFALO, N.Y., March 19, 2014 /PRNewswire/ -- Kinex Pharmaceuticals announced today to having received regulatory and ethics approvals to initiate the first clinical study of an oral form of paclitaxel (Oraxol) in Dunedin Hospital in Otago, New Zealand. This is the first clinical study of Oraxol in New Zealand. Oraxol is also currently in clinical studies conducted in Korea and in the United States of America. Dr. Rudolf Kwan, Chief Medical Officer of Kinex stated "Kinex is...

2014-03-04 12:26:47

BUFFALO, N.Y. and HONG KONG, March 4, 2014 /PRNewswire/ -- Kinex Pharmaceuticals announced today the successful completion of an oversubscribed USD $40 million private placement of equity which was completed on February 28, 2014. Proceeds from this round, coupled with cash on hand, will be used to fund the completion of the commercialization of its oral form of paclitaxel (Oraxol) and irinotecan (Oratecan) in select markets outside of the United States. In addition, the proceeds will...

2014-02-06 08:29:23

BUFFALO, N.Y., Feb. 6, 2014 /PRNewswire/ -- Kinex Pharmaceuticals and PharmaEssentia Corporation (Taiwan) announced today the execution of a new licensing agreement granting PharmaEssentia exclusive development and commercial rights to Oraxol and Oratecan in Taiwan and Singapore. Kinex will receive an upfront payment, milestones, and royalties. PharmaEssentia has also committed to conducting clinical studies in Taiwan to contribute to the global registration programs for Oraxol...

2014-02-05 08:30:51

BUFFALO, N.Y., Feb. 5, 2014 /PRNewswire/ -- Kinex Pharmaceuticals, (Kinex), a leading specialty biotech focused on the development and commercialization of next generation oral therapies for cancer diseases has appointed Dr. Rudolf Kwan, as Chief Medical Officer and Dr. Wing-Kai Chan as Head of Clinical Operations- Asia/Pacific. Kinex currently has four oral oncology drug candidates allowed in the clinic and the appointments of Dr. Kwan and Dr. Chan adds significant expertise in...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related